The London-based investment firm has acquired the pan-European provider of cancer care services.
London-based investment firm Fremman Capital is to acquire Amethyst, a pan-European provider of cancer care services headquartered in London, from its founding shareholders and asset managers The Rohatyn Group.
Financial terms have not been disclosed.
A report from Brussels-based trade association The European Federation of Pharmaceutical Industries and Associations has highlighted both growing interest in the sector but also a broader shift toward consolidation and innovation within the industry. It describes the landscape as “complex and fragmented”.
“Amethyst fits perfectly into our strategy of supporting market-leading providers of essential services. With our deep healthcare experience and international reach, we’re excited to work with Amethyst to accelerate growth and build a European champion in radiotherapy,” said Edward Chandler, founding partner at Fremman Capital.
In June last year, the firm inked a €300 million (£256 million) financing agreement with global alternative investment manager Ares Management Corporation.
Founded in 2010, Amethyst operates one of the largest independent networks of cancer treatment centres in Europe, with 19 centres across France, Poland, Romania, the UK, Italy, and Austria. It treats more than 50,000 patients every year.
Amethyst has around 100 doctors and a team of over 500 professionals. Its infrastructure includes around 40 linear accelerators, the technology used to deliver radiotherapy treatments.
